{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:08:02Z","timestamp":1790726882539,"version":"4.1.0"},"reference-count":33,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,5,30]]},"DOI":"10.18632\/oncotarget.3880","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:31:59Z","timestamp":1442298719000},"page":"13462-13475","source":"Crossref","is-referenced-by-count":60,"title":["Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer"],"prefix":"10.18632","volume":"6","author":[{"given":"Julie","family":"Jacobs","sequence":"first","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"},{"name":"Department of Pathology, Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zwaenepoel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"},{"name":"Department of Oncology, Antwerp University Hospital, Edegem, Belgium"},{"name":"Phase 1-Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Van den Bossche","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Deben","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Silence","sequence":"additional","affiliation":[{"name":"arGEN-X BVBA, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hermans","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"},{"name":"Department of Pathology, Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Smits","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"},{"name":"Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, Antwerp University, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Van Schil","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Lardon","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Deschoolmeester","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"},{"name":"Department of Pathology, Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pauwels","sequence":"additional","affiliation":[{"name":"Center for Oncological Research Antwerp, Center for Oncological Research Antwerp (CORE), Antwerp University, Wilrijk, Belgium"},{"name":"Department of Pathology, Antwerp University Hospital, Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,4,19]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Findlay","year":"2005","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ctrv.2014.05.009","article-title":"Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors","volume":"40","author":"Van Meerbeeck","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Hu","year":"2011","journal-title":"Lancet Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"O'Byrne","year":"2013","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Riely","year":"2013","journal-title":"Clin Cancer Res"},{"key":"6","first-page":"4","article-title":"Lung: non-small cell lung carcinoma","volume":"8","author":"Heighway","year":"2004","journal-title":"Atlas of Genetics and Cytogenetics in oncology and haematology"},{"key":"7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Ward","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.PPO.0000581876.62921.87","article-title":"Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma","volume":"18","author":"Wolchok","year":"2012","journal-title":"Cancer J"},{"key":"9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1586\/14737140.2014.952287","article-title":"Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?","volume":"14","author":"Raez","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2567.2006.02550.x","article-title":"CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells","volume":"121","author":"Gaston","year":"2007","journal-title":"Immunology"},{"key":"11","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood-2007-03-082578","article-title":"CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells","volume":"110","author":"Ansell","year":"2007","journal-title":"Blood"},{"key":"12","first-page":"15","article-title":"Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology","volume":"229","author":"van Lier","year":"2009","journal-title":"Immunological Reviews"},{"key":"13","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-05-2883","article-title":"Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates","volume":"66","author":"Doronina","year":"2006","journal-title":"Cancer Res"},{"key":"14","first-page":"2592","article-title":"Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma","volume":"62","author":"Weller","year":"2002","journal-title":"Cancer Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1182\/blood.V85.12.3556.bloodjournal85123556","article-title":"Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells","volume":"85","author":"Kipps","year":"1995","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.exphem.2005.10.005","article-title":"Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL","volume":"33","author":"Chiodi","year":"2005","journal-title":"Exp Hematol"},{"key":"17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/clin.1996.0184","article-title":"Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus","volume":"81","author":"Ingelmo","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4049\/jimmunol.147.1.29","article-title":"A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR\/CD3 complex","volume":"147","author":"van Lier","year":"1991","journal-title":"J Immunol"},{"key":"19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000070661","article-title":"Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma","volume":"24","author":"Kersten","year":"2003","journal-title":"Tumour Biol"},{"key":"20","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","article-title":"Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs","volume":"19","author":"Stagg","year":"2013","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/mabs.27398","article-title":"ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade","volume":"6","author":"De Haard","year":"2014","journal-title":"MAbs"},{"key":"22","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shitara","year":"2003","journal-title":"J Biol Chem"},{"key":"23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Dranoff","year":"2011","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2009.08.031","article-title":"Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer","volume":"115","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"25","first-page":"615","article-title":"Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas","volume":"6","author":"Yu","year":"2013","journal-title":"Onco Targets Ther"},{"key":"26","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.4049\/jimmunol.0804305","article-title":"CD27 expression on CD4+ T cells differentiates effector from regulatory T cell subsets in the lung","volume":"182","author":"Fontenot","year":"2009","journal-title":"J Immunol"},{"key":"27","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","article-title":"CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth","volume":"72","author":"Ochsenbein","year":"2012","journal-title":"Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3109\/10428194.2012.660627","article-title":"Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone","volume":"53","author":"Seishima","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"29","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1182\/blood-2007-04-084525","article-title":"CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia","volume":"112","author":"Patterson","year":"2008","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3816\/CLML.2011.n.041","article-title":"Matrix metalloproteinase-8 is overexpressed in Waldenstrom's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27","volume":"11","author":"Treon","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"31","first-page":"329","article-title":"A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes","volume":"31","author":"Snijders","year":"2009","journal-title":"Cell Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/his.12414","article-title":"Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements-comparison of multiple immunohistochemical methods","volume":"65","author":"Pauwels","year":"2014","journal-title":"Histopathology"},{"key":"33","doi-asserted-by":"crossref","first-page":"e46536","DOI":"10.1371\/journal.pone.0046536","article-title":"Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays","volume":"7","author":"Pauwels","year":"2012","journal-title":"PLoS One"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T03:26:56Z","timestamp":1691983616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,19]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,5,30]]}},"alternative-id":["3880","25951351"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3880","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,19]]}}}